Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Yang, Deok-Hwan | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Lee, Se-Ryeon | - |
dc.contributor.author | Lee, Gyeong-Won | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Kim, Ho Young | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Kim, Hugh Chul | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Chung, Jooseop | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Ryoo, Baek-Yeol | - |
dc.date.available | 2020-02-29T06:43:02Z | - |
dc.date.created | 2020-02-05 | - |
dc.date.issued | 2012-04 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16477 | - |
dc.description.abstract | We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2) and vincristine 1.4 mg/m(2) (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.subject | B-CELL LYMPHOMA | - |
dc.subject | ANTI-CD20 MONOCLONAL-ANTIBODY | - |
dc.subject | NON-HODGKINS-LYMPHOMA | - |
dc.subject | ADVANCED FOLLICULAR LYMPHOMA | - |
dc.subject | TISSUE LYMPHOMA | - |
dc.subject | MALT TYPE | - |
dc.subject | CHOP CHEMOTHERAPY | - |
dc.subject | FLUDARABINE PHOSPHATE | - |
dc.subject | CLINICAL PRESENTATION | - |
dc.subject | ORAL FLUDARABINE | - |
dc.title | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000301243600009 | - |
dc.identifier.doi | 10.1007/s00277-011-1337-6 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.91, no.4, pp.543 - 551 | - |
dc.identifier.scopusid | 2-s2.0-84860805905 | - |
dc.citation.endPage | 551 | - |
dc.citation.startPage | 543 | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 91 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Park, Jinny | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | CVP | - |
dc.subject.keywordAuthor | First-line | - |
dc.subject.keywordAuthor | Immunochemotherapy | - |
dc.subject.keywordAuthor | Marginal zone lymphoma | - |
dc.subject.keywordAuthor | Rituximab | - |
dc.subject.keywordPlus | B-CELL LYMPHOMA | - |
dc.subject.keywordPlus | ANTI-CD20 MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | NON-HODGKINS-LYMPHOMA | - |
dc.subject.keywordPlus | ADVANCED FOLLICULAR LYMPHOMA | - |
dc.subject.keywordPlus | TISSUE LYMPHOMA | - |
dc.subject.keywordPlus | MALT TYPE | - |
dc.subject.keywordPlus | CHOP CHEMOTHERAPY | - |
dc.subject.keywordPlus | FLUDARABINE PHOSPHATE | - |
dc.subject.keywordPlus | CLINICAL PRESENTATION | - |
dc.subject.keywordPlus | ORAL FLUDARABINE | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.